Published : Dec-2019
No. of Pages : 297
1.1 List of Tables 7
1.2 List of Figures 11
2 Introduction 13
2.1 Topical Absorbable Hemostats Overview 13
3 Products under Development 14
3.1 Topical Absorbable Hemostats - Pipeline Products by Stage of Development 14
3.2 Topical Absorbable Hemostats - Pipeline Products by Segment 15
3.3 Topical Absorbable Hemostats - Pipeline Products by Territory 16
3.4 Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 17
3.5 Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 18
3.6 Topical Absorbable Hemostats - Ongoing Clinical Trials 19
4 Topical Absorbable Hemostats - Pipeline Products under Development by Companies 20
4.1 Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development 20
4.2 Topical Absorbable Hemostats - Pipeline Products by Stage of Development 22
5 Topical Absorbable Hemostats Companies and Product Overview 24
5.1 3-D Matrix Ltd Company Overview 24
5.2 Angiotech Pharmaceuticals Inc Company Overview 30
5.3 Anika Therapeutics Inc Company Overview 31
5.4 APRUS Bio-Medical Innovations Pvt Ltd Company Overview 32
5.5 Arch Therapeutics Inc Company Overview 33
5.6 Baxter Healthcare Corp Company Overview 38
5.7 Baxter International Inc Company Overview 39
5.8 Beth Israel Deaconess Medical Center Inc Company Overview 52
5.9 Biomedica Management Corp Company Overview 53
5.10 Biom'Up SAS Company Overview 56
5.11 C. R. Bard Inc Company Overview 57
5.12 Cellphire Inc Company Overview 59
5.13 Ceramicos Para Aplicacoes Medicas SA Company Overview 63
5.14 Columbia University Company Overview 64
5.15 Covalent Medical, Inc. (Inactive) Company Overview 65
5.16 Covalon Technologies Ltd Company Overview 66
5.17 Cresilon Inc Company Overview 68
5.18 CryoLife Inc Company Overview 70
5.19 Endomedix Incorporated Company Overview 71
5.20 Entegrion Inc Company Overview 73
5.21 Ethicon US LLC Company Overview 74
5.22 ETX Pharma Inc Company Overview 76
5.23 Gamma Therapeutics Inc Company Overview 77
5.24 GATT Technologies BV Company Overview 78
5.25 gel-e Inc Company Overview 80
5.26 Haemostatix Ltd Company Overview 82
5.27 Hemostasis LLC Company Overview 84
5.28 HLL Lifecare Ltd Company Overview 86
5.29 Keratin Biosciences Inc Company Overview 87
5.30 Leader Biomedical Europe BV Company Overview 88
5.31 LifeBond Ltd Company Overview 89
5.32 Protege Biomedical Company Overview 90
5.33 Resorba GmbH Company Overview 91
5.34 Rice University Company Overview 93
5.35 Sanara MedTech Inc Company Overview 94
5.36 Sanofi Biosurgery Inc Company Overview 95
5.37 Sea Run Holdings Inc Company Overview 97
5.38 St Teresa Medical Inc Company Overview 98
5.39 Tectum Company Overview 100
5.40 The Medicines Company Company Overview 102
5.41 Therus Corporation Company Overview 103
5.42 Thrombotargets Corp Company Overview 104
5.43 United Health Products, Inc. Company Overview 108
5.44 University of Grenoble Alpes Company Overview 111
5.45 Virginia Commonwealth University Company Overview 112
5.46 Xcede Technologies Inc Company Overview 113
6 Topical Absorbable Hemostats- Recent Developments 116
6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 116
6.2 Nov 12, 2019: Cook Medical's leadership updates in Asia-pacific reinforce focus on growth and physician relationships 118
6.3 Nov 05, 2019: Stryker signs agreement to acquire Wright Medical for $5.4bn 119
6.4 Oct 31, 2019: gel-e announces breakthrough status designation from the U.S. Food and Drug Administration (FDA) for its first internal-use flowable device 119
6.5 Oct 31, 2019: Sanofi Q3 well on track 120
6.6 Oct 30, 2019: The Medicines Company reports third-quarter 2019 financial results and achievement of major milestones for inclisiran 123
6.7 Oct 30, 2019: CryoLife reports third quarter 2019 financial results 125
6.8 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 126
6.9 Oct 24, 2019: Baxter reports preliminary third quarter 2019 operating results 129
6.10 Oct 24, 2019: Anika reports third quarter 2019 financial results 131
7 Appendix 293
7.1 Methodology 293
7.2 About GlobalData 296
7.3 Contact Us 296
7.4 Disclaimer 296
List of Tables
Table 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 15
Table 2: Topical Absorbable Hemostats - Pipeline Products by Segment 16
Table 3: Topical Absorbable Hemostats - Pipeline Products by Territory 17
Table 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 18
Table 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 19
Table 6: Topical Absorbable Hemostats - Ongoing Clinical Trials 20
Table 7: Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development 21
Table 8: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 23
Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
Table 10: PuraStat Hemostat - Product Status 26
Table 11: PuraStat Hemostat - Product Description 26
Table 12: TDM-511 - Product Status 27
Table 13: TDM-511 - Product Description 27
Table 14: TDM-623 - Product Status 27
Table 15: TDM-623 - Product Description 27
Table 16: 3-D Matrix Ltd - Ongoing Clinical Trials Overview 28
Table 17: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding after Open Liver Resection 29
Table 18: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery 29
Table 19: PuraStat Hemostat - A Multicenter Prospective Observational Study to Evaluate the Utilization, Effectiveness and Safety of Purastat in the Management of Gastrointestinal Bleeding 30
Table 20: PuraStat Hemostat - The Hemostatic Potential of TDM-621 on Ascending Aortic Surgery 30
Table 21: Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 22: Hemaseel Thrombin Haemostatic Agent - Product Status 31
Table 23: Hemaseel Thrombin Haemostatic Agent - Product Description 31
Table 24: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 32
Table 25: Hemostatic Patch - Product Status 32
Table 26: Hemostatic Patch - Product Description 32
Table 27: APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
Table 28: Deep Wound Hemostat - Product Status 33
Table 29: Deep Wound Hemostat - Product Description 33
Table 30: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 34
Table 31: AC5 - V - Product Status 34
Table 32: AC5 - V - Product Description 34
Table 33: AC5 Surgical Hemostatic Device - Product Status 35
Table 34: AC5 Surgical Hemostatic Device - Product Description 35
Table 35: AC5 Topical Gel - Product Status 35
Table 36: AC5 Topical Gel - Product Description 36
Table 37: Arch Therapeutics Inc - Ongoing Clinical Trials Overview 37
Table 38: AC5 Topical Gel - AC5 Topical Gel Skin Sensitization Study 38
Table 39: Baxter Healthcare Corp Pipeline Products & Ongoing Clinical Trials Overview 39
Table 40: Celstat Topical Hemostatic Dressing - Product Status 39
Table 41: Celstat Topical Hemostatic Dressing - Product Description 39
Table 42: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 40
Table 43: FloSeal Matrix Hemostatic Sealant - Product Status 40
Table 44: FloSeal Matrix Hemostatic Sealant - Product Description 41
Table 45: Hemopatch - Product Status 41
Table 46: Hemopatch - Product Description 41
Table 47: Hemopatch - Dural Defects - Product Status 42
Table 48: Hemopatch - Dural Defects - Product Description 42
Table 49: TISSEEL - Product Status 42
Table 50: TISSEEL - Product Description 43
Table 51: Baxter International Inc - Ongoing Clinical Trials Overview 44
Table 52: FloSeal Matrix Hemostatic Sealant - Blood-saving Effect of Combined Intravenous Tranexamic Acid with Topical Floseal Application, a Comparison with Intravenous Tranexamic Acid Only in Total Hip Arthroplasty 46
Table 53: FloSeal Matrix Hemostatic Sealant - Effectiveness of Gelatin Matrix with Human Derived Thrombin on Blood Loss, Surgical Time, Hospital Stay and Complications in Adolescents Undergoing Spine Surgery for Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial 46
Table 54: FloSeal Matrix Hemostatic Sealant - Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery 46
Table 55: FloSeal Matrix Hemostatic Sealant - Impact of Electrocoagulation Versus a Gelantine-Thrombin Matrix Sealant (FloSeal) on Ovarian Reserve After Laparoscopic Stripping of Ovarian Endometriomas 47
Table 56: FloSeal Matrix Hemostatic Sealant - Intraoperative Bleeding Control with Thrombin-Gelatin-Matrix (Floseal) in Advanced Gynecologic Surgery. A Case-control Study with Special Focus on Hemostasis in Patients with Primary or Secondary Coagulapathies 47
Table 57: FloSeal Matrix Hemostatic Sealant - Management of Persistent Anterior Epistaxis Using Floseal Hemostatic Matrix vs. Traditional Nasal Packing: A Prospective Randomized Controlled Trial 47
Table 58: FloSeal Matrix Hemostatic Sealant - Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat with FLOSEAL Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery 48
Table 59: FloSeal Matrix Hemostatic Sealant - The Role of Floseal in the Prevention of Lymphocele and Lymphatic Ascites After Lymph Node Dissection for Gynecologic Cancer: a Randomized Controlled Trial 48
Table 60: TISSEEL - Modified Muller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue 49
List of Figures
Figure 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 15
Figure 2: Topical Absorbable Hemostats - Pipeline Products by Segment 16
Figure 3: Topical Absorbable Hemostats - Pipeline Products by Territory 17
Figure 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 18
Figure 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 19
Figure 6: Topical Absorbable Hemostats - Ongoing Clinical Trials 20
